Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 84-89

  Ballanger, Benedicte ^a   Klinger, Helene ^b   Eche, Julien ^c   Lerond, Jérôme ^c   Vallet, Anne Evelyne ^b   Le Bars, Didier ^b,d   Tremblay, Leon ^a   Sgambato Faure, Véronique ^a   Broussolle, Emmanuel ^a,b   Thobois, Stéphane ^a,b  

^a INSTITUT DES SCIENCES COGNITIVES   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d CERMEP IMAGERIE DU VIVANT   (France)

Author keywords

18F MPPF; Depression; Parkinson; PET; Serotonin

Indexed keywords

SEROTONIN 1A RECEPTOR;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; INSULA; MALE; ORBITAL CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONERGIC SYSTEM DYSFUNCTION; SEROTONINERGIC SYSTEM; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY;

ADULT; AGED; AMINOPYRIDINES; BRAIN; DEPRESSION; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS;

EID: 84855920924     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23895     Document Type: Article

References (45)

1. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009; 24: 2175-2186.
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009; 8: 464-474.
3. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999; 166: 141-151.
4. Murai T, Müller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001; 13: 222-228.
5. Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003; 10: 399-406.
6. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128: 1314-1322.
7. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med. 2005; 46: 227-232.
8. Koerts J, Leenders KL, Koning M, et al. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci. 2007; 25: 3132-3136.
9. Czernecki V, Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008; 23: 964-969.
10. Hesse S, Meyer PM, Strecker K, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imaging. 2009; 36: 428-435.
11. Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain. 2010; 133: 1111-1127.
12. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010; 9: 573-580.
13. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007; 78: 641-643.
14. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991; 50: 743-755.
15. Kish S. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol. 2003; 91: 39-49.
16. Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab. 2008; 28: 441-444.
17. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003; 60: 1223-1229.
18. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol. 2007; 14: 523-528.
19. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008; 23: 1776-1780.
20. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010; 75: 1920-1927.
21. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol. 1989; 15: 27-44.
22. Fahn S, Elton RL for the UPDRS Development Commitee Unified Parkinson's disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Development in Parkinson's Disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information; 1987: 153-163.
23. Costes N, Merlet I, Ostrowsky K, et al. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med. 2005; 46: 1980-1989.
24. Gunn RN, Sargent PA, Bench CJ, et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage. 1998; 8: 426-440.
25. Costes N, Merlet I, Zimmer L, et al. Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab. 2002; 22: 753-765.
26. Parsey RV, Arango V, Olvet DM, et al. Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab. 2005; 25: 785-793.
27. Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med. 1979; 9: 139-145.
28. Feldmann A, Illes Z, Kosztolanyi P, et al. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov Disord. 2008; 23: 42-46.
29. Kostić VS, Agosta F, Petrović I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010; 75: 857-863.
30. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol. 1990; 28: 57-64.
31. Matsui H, Nishinaka K, Oda M, et al. Minor depression and brain perfusion images in Parkinson's disease. Mov Disord. 2006; 21: 1169-1174.
32. Cardoso EF, Maia FM, Fregni F, et al. Depression in Parkinson's disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage. 2009; 47: 467-472.
33. Lesch KP, Gutknecht L. Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol. 2004; 7: 381-385.
34. Wang RY, Aghajanian GK. Antidromically identified serotonergic neurons in the rat midbrain raphe: evidence for collateral inhibition. Brain Res. 1977; 132: 186-193.
35. Bernheimer H, Birkmayer W, Hornykiewicz O. Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome. Klin Wochenschr. 1961; 39: 1056-1059.
36. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord. 2009; 24: 1255-1266.
37. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009; 88: 17-31.
38. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997; 12: 756-759.
39. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000; 15: 986-989.
40. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999; 46: 1375-1387.
41. Meltzer CC, Price JC, Mathis CA, et al. Serotonin 1A receptor binding and treatment response in late-life depression1. Neuropsychopharmacology. 2004; 29: 2258-2265.
42. Moses-Kolko EL, Wisner KL, Price JC, et al. Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril. 2008; 89: 685-692.
43. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007; 62: 870-877.
44. Shively CA, Friedman DP, Gage HD, et al. Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys. Arch Gen Psychiatry. 2006; 63: 396-403.
45. Hesse S, Barthel H, Schwarz J, et al. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev. 2004; 28: 547-563.